At Targenta, our mission is to facilitate effective healthcare collaboration leading to quicker and smoother patient pathways. We do that by facilitating secure and effective communication among medical professionals and providing them with solutions that help them reduce their administrative burden.

We envision a future where diverse and empowered medical teams to collectively design patient pathways and medication schedules, ensuring seamless coordination among the collective of healthcare professionals.Our vision encompasses a future where healthcare professionals can access personalized diagnostic and therapeutic insights with ease, leading to improved patient well-being and a more cost-effective healthcare system overall.

We remain committed to innovation, quality, and continuous improvement. We strive to be at the forefront of technological advancements, offering tailored solutions that meet the evolving needs of medical professionals and healthcare providers. Through strategic partnerships, investments, and a relentless dedication to our goals, we aim to shape the future of healthcare, making it more efficient, accessible, and patient-centric.

We offer a comprehensive suite of cloud-based solutions tailored to meet the needs of modern healthcare professionals:

The Medical Team Dashboard System (MDS) is a user-friendly cloud platform designed to facilitate remote collaboration among medical professionals. It allows healthcare teams to securely access, discuss, and provide diagnostic or therapeutic recommendations for patient cases. With features like customizable authentications and access management, the MDS promotes flexibility and data security.

Tailored Treatment Options: Our platform provides personalized diagnostic and therapeutic recommendations based on a carefully curated database linking diseases to therapies and diagnostics. Healthcare professionals can input patient data using universal ICD codes, enabling them to access customized recommendations efficiently.

PharmaSolv is a sophisticated tool that analyzes patient medication, ICD codes, and conditions to provide insights on potential drug interactions and optimized medication schedules. By suggesting replacement drugs and offering personalized dosage and timing recommendations, PharmaSolv ensures medication safety and coordination of care. For more detailed descriptions and subscription plan options visit our Services page here

• Medical Practices and Clinics - whether operating in single or multi-location settings, our services facilitate secure communication among your colleagues and streamline decision-making for improved patient care.

• Hospitals and Healthcare Facilities - larger healthcare facilities can benefit from Targenta's solutions to optimize workflow efficiency and patient outcomes across departments and specialties. Our services help bridge communication gaps and ensure seamless coordination of care for patients receiving treatment from multiple providers. PharmaSolv medication optimizer app is a great facilitator of healtcare work in fast-paced environments.

• Pharmacies and Pharmacist Teams - working in the pharma field you can leverage Targenta's PharmaSolv tool to enhance medication safety and optimize prescription management. By identifying potential drug interactions and providing personalized dosage recommendations, PharmaSolv supports pharmacists in delivering high-quality pharmaceutical care.

• Healthcare Networks and Collaborative Partnerships - Targenta's services are well-suited for healthcare networks and collaborative partnerships aiming to improve care coordination and patient outcomes across multiple organizations. Our solutions facilitate secure communication and data sharing among network members, promoting a holistic approach to patient care.

• Private Dental and Oral Care Centers - making educated decisions regarding dental care or oral surgeries is a must - do that with having your Clients' medical data in order and having the possibility to communiate with your Clients' doctors workig in other institutions! Whether operating in a uni- or multi-location settings, our services facilitate secure communication and streamline decision-making for improved quality in your services.

• Targeted drug combination therapy design based on driver genes. Zsákai L et al., Oncotarget, 2019

• Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. Simon-Szabó L et al., Bioorg Med Chem Lett. 2016

• Complex regulation of autophagy in cancer – integrated approaches to discover the networks that hold a double-edged sword. Kubisch J et al., Sem Cancer Biol. 2013

• Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Ho HK et al., Curr Med Chem. 2013

• Mycobacterium tuberculosis ellenes hatoanyagok fejlesztése es szerkezet-hatás összefuggéseinek vizsgálata. Baska F et al., Acta Pharm Hung. 2013

• SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks. Fazekas D et al., BMC Syst Biol. 2013

• Potenciális antitumor hatású FGFR inhibitorok fejlesztése, Zsákai L et al., Acta Pharm Hung. 2013

• WO2017153789: Benzo[b]thiophene derivatives and their use for the inhibition of Fibroblast Growth Factor Receptor kinases (FGFRs) for the use of neo- and hyperplasia

• WO2015019121: Styrylquinazoline derivatives as pharmaceutically active agents

• P1500431: Pyrido pyrimidine derivatives as pharmaceutically active agents

• P1500620: Novel use of kinase antagonist compounds to alter fibrotic cell proliferation

• A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling. Székely R et al., Immunology Letters, 2008

• Regulation of influenza A virus mRNA splicing by CLK1. Artarini A et al., Antiviral research 2019

• Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release. Orfi Z et al. European Journal of Cancer, 2014

• Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. E Herczenik, Z Varga, D Erős, V Makó, M Oroszlán, S Rugonfalvi-Kiss: Journal of Receptors and Signal Transduction 29 (2), 75-83, 2009

• Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino acids, 2009

• Signal transduction therapy with rationally designed kinase inhibitors. Keri G et al., Current Signal Transduction Therapy, 2006

• Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis. Hegymegi-Barakonyi B et al., Curr Med Chem. 2008;15(26):2760-70

• Targeted drug combination therapy design based on driver genes, Zsákai L et al., Oncotarget, 2019

• Reliability of logP predictions based on calculated molecular descriptors: A critical review. Erős D et al, Curr. Med. Chem. 2002

• Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. Hollósy F et al., Journal of Chromatography B, 2002

• Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high- performance liquid chromatography, clogP calculation and cytotoxicity test. Hollósy F et al., Journal of Chromatography B, 2002

• Evaluation of hydrophobicity and antitumor activity of a molecule library of Mannich ketones of cycloalkanones. Hollósy F et al., Journal of Liquid Chromatography and Related Technologies, 2002

• Biological activity and structure of antitumor compounds from Plantago media. Kunvari M et al., Acta Pharmaceutica Hungarica, 1999

• Comparison of Predictive Ability of Water Solubility QSPR Models Generated by MLR, PLS and ANN Methods. Erős D et al., Mini-Reviews in Medicinal Chemistry 2004

• Determination of the basicity of Mannich ketones by capillary electrophoresis. Dobos Zs et al., Journal of Chromatography B, 2004

• Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. Hallgas B et al., Journal of Chromatography B, 2004

• Rational Drug Design and Signal Transduction Therapy. Erős D et al., Pharmacem, 2004

• Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Szekelyhidi Z et al., Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.

• Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. Hallgas B et al., J Chromatogr B Analyt Technol Biomed Life Sci. 2005

• Prediction oriented QSAR modelling of EGFR inhibition. Szantai-Kis C et al., Curr. Med. Chem., 2006

• MIF tautomerase inhibitor potency of alpha,beta-unsaturated cyclic ketones. Garai J et al., Int Immunopharmacol.

• Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Kiss R et al., Eur J Med Chem. 2007

• Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Kéri G et al., Assay Drug Dev Technol. 2005

• Structure –Activity Relationships of PDE5 Inhibitors. Erős D et al., Current Medicinal Chemistry, Volume 15, Number 16, 2008. Pp. 1570-1585.

• Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino Acids. 2009

• Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. Herczenik E et al., Journal of Receptors and Signal Transduction, 2009

• Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Hegymegi-Barakonyi B et al., Curr Opin Mol Ther. 2009

• EP3056202: Benzopyrolidone derivatives possessing antiviral and anticancer properties

• Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha- synuclein. Oláh J, et al., J Biol Chem. 2011

• A foldamer-dendrimer conjugate neutralizes synaptotoxic β-amyloid oligomers. Fülöp L et al., PLoS One. 2012

• Protein array based interactome analysis of amyloid-β indicates an inhibition of protein translation. Virok DP et al., J Proteome Res. 2011

• Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer's disease. Lakatos A et al., Dalton Trans. 2010

• Controlled in situ preparation of A beta(1-42) oligomers from the isopeptide "iso-A beta(1-42)", physicochemical and biological characterization. Bozso Z et al., Peptides. 2010

• Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. Balogh et al., Frontiers in Immunology, 2019

• A versatile modular vector set for optimizing protein expression among bacterial, yeast, insect and mammalian hosts. PLoS One, 2019

• CR3 is the dominant phagocytotic complement receptor on human dendritic cells. Sándor et al., Immunobiology, 2013

• Cutting Edge: A New Player in the Alternative Complement Pathway, MASP-1 Is Essential for LPS-Induced, but Not for Zymosan-Induced, Alternative Pathway Activation. Paréj et al., Journal of Immunology, 2014

• Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Paréj et al., Molecular Immunology, 2014

• The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not. Paréj et al., Molecular Immunology, 2013

• Cell-type specific arousal-dependent modulation of thalamic activity in the lateral geniculate nucleus. Molnár et al., Cerebral Cortex Communications, 2021

• Reciprocal lateral hypothalamic and raphé GABAergic projections promote wakefulness. Gazea et al., The Journal of Neuroscience, 2021

• On technical issues please contact us via admin@targenta.org or via WhatsApp +358 41 7288 443

• Regarding questions related to services, buisness development and invoicing please contact Lilian Zsakai via lilian.zsakai@targenta.org or via WhatsApp +358 41 7288 443 or via LinkedIn messaging

Full name: Targenta Oy

Year of establishment: 2024

Registered seat: Leija Yrityskeskus, Elannontie 3, 01510, Vantaa

Y-tunnus: 3422405-3

Main activity: 62010 ohjelmistojen suunnittelu ja valmistus (software development)